Analyzing Absci (ABSI) and Its Rivals

Absci (NASDAQ:ABSIGet Rating) is one of 40 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its peers? We will compare Absci to similar businesses based on the strength of its institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Absci and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Absci 1 3 3 0 2.29
Absci Competitors 39 576 1184 22 2.65

Absci currently has a consensus price target of $20.40, indicating a potential upside of 444.00%. As a group, “Commercial physical research” companies have a potential upside of 58.33%. Given Absci’s higher possible upside, equities analysts plainly believe Absci is more favorable than its peers.

Earnings and Valuation

This table compares Absci and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Absci $4.78 million -$100.96 million -1.13
Absci Competitors $2.80 billion $97.54 million 12.81

Absci’s peers have higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

40.0% of Absci shares are owned by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 11.4% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Absci and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Absci -2,633.14% -36.19% -22.99%
Absci Competitors -260.35% -8.17% -2.92%

Summary

Absci peers beat Absci on 11 of the 12 factors compared.

About Absci (Get Rating)

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Want More Great Investing Ideas?

Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.